Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Ipilimumab in Pediatric High Grade CNS Malignancies
NCT03130959Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2017
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 2, open-label trial of nivolumab in diffuse intrinsic pontine glioma (DIPG), high-grade glioma (HGG), medulloblastoma and 1 more (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Dose Limiting Toxicities up to 6 weeks, Serious Adverse Events up to 6 weeks and 2 more. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
diffuse intrinsic pontine glioma (DIPG)high-grade glioma (HGG)medulloblastomaependymoma
Beyond the preview
Go deeper on NCT03130959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03130959.